Evidence map›Paper›PMID 33851158›Full record

ArticlebioRxiv : the preprint server for biology2021

Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality.

Jule Goike, Ching-Lin Hsieh, Andrew Horton, Elizabeth C Gardner, Foteini Bartzoka, Nianshuang Wang, Kamyab Javanmardi, Andrew Herbert, Shawn Abbassi, Rebecca Renberg and 30 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 6 institutions in 1 country.

Jule Goike *Center for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ching-Lin Hsieh *Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Andrew Horton *Center for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Elizabeth C Gardner *Center for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Foteini BartzokaCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Nianshuang WangDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Kamyab JavanmardiCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Andrew HerbertU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
Shawn AbbassiU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
Rebecca RenbergCCDC Army Research Laboratory, Biotechnology Branch, Adelphi, MD, USA.
Michael J JohansonNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Jose A CardonaCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Thomas Segall-ShapiroCCDC Army Research Laboratory-South, Austin, TX, USA.
Ling ZhouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ruth H NisslyDepartment of Veterinary and Biomedical Science and Animal Diagnostic Laboratory, The Pennsylvania State University, University Park, Pennsylvania, USA.
Abhinay GontuDepartment of Veterinary and Biomedical Science and Animal Diagnostic Laboratory, The Pennsylvania State University, University Park, Pennsylvania, USA.
Michelle ByromCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Andre C MaranhaoCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Anna M BattenhouseCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Varun GejjiNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Laura Soto-SierraNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Emma R FosterNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Susan L WoodardNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Zivko L NikolovNational Center for Therapeutics Manufacturing, Texas A&M University, College Station, TX, USA.
Jason LavinderDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Will N VossDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ankur AnnapareddyCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Gregory C IppolitoCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Andrew D EllingtonCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Edward M MarcotteCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Ilya J FinkelsteinCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Randall A HughesCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
James M MusserCenter for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
Suresh V KuchipudiDepartment of Veterinary and Biomedical Science and Animal Diagnostic Laboratory, The Pennsylvania State University, University Park, Pennsylvania, USA.
Vivek KapurDepartment of Animal Science and the Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.
George GeorgiouCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
John M DyeU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
Daniel R BoutzCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Jimmy D GolliharCenter for Systems and Synthetic Biology, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
The University of Texas at Austin · USTexas A&M University · USPennsylvania State University · USUnited States Army Medical Research Institute of Infectious Diseases · USHouston Methodist · USDEVCOM Army Research Laboratory · US

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Proteomics and model organism humanization to decode human geneticsR35GM122480 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI EDWARD M MARCOTTE · 2017 to 2026
$5.4M
Novel delivery platform and antigen design for an effective COVID-19 vaccineR01AI158177 · NIAID · PURDUE UNIVERSITY · PI MITTAL, SURESH K · 2020 to 2025
$3.9M
Structure, Function and Antigenicity of Coronavirus Spike ProteinsR01AI127521 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MCLELLAN, JASON SCOTT, WARD, ANDREW BARRETT · 2017 to 2021
$3.1M
NIAID NIH HHS R01 AI127521NIAID NIH HHS R01 AI158177NIGMS NIH HHS P41 GM103311NIGMS NIH HHS R35 GM122480
6 · The paper itself

Abstract

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has sparked concern over the continued effectiveness of existing therapeutic antibodies and vaccines. Hence, together with increased genomic surveillance, methods to rapidly develop and assess effective interventions are critically needed. Here we report the discovery of SARS-CoV-2 neutralizing antibodies isolated from COVID-19 patients using a high-throughput platform. Antibodies were identified from unpaired donor B-cell and serum repertoires using yeast surface display, proteomics, and public light chain screening. Cryo-EM and functional characterization of the antibodies identified N3-1, an antibody that binds avidly (K

Identifiers

PMID33851158
PMCPMC8043448
OpenAlexW3140017811

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.